Much like multiple myeloma, the treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies, says Michael Rosenzweig, MD.
Daratumumab (Darzalex) has been shown to induce deep and rapid hematologic responses in pretreated patients with AL amyloidosis. Results from a prospective phase II study showed that the hematologic complete response rate was 17% in 24 evaluable patients. Additionally, 29% of patients experienced a very good partial response, and 17% achieved a partial response. The overall response rate for daratumumab in this population was 63%.
Early data for the novel anti-amyloid fibril therapy, 11-1F4, also known as CAEL-101, have suggested preliminary signals of efficacy as well, said Rosenzweig.